TOL-3021 Phase 2a clinical trial press release Tolerion Inc. 321
Dedalera Dr. Portola Valley, CA  94028  Tolerion Inc. is a newly
formed clinical-stage biopharmaceutical company at the forefront
of developing novel and targeted treatment candidates for
autoimmune diseases. Leveraging its proprietary reverse vaccine
platform, Tolerion’s product candidates are designed to restore
a patient’s immune system “tolerance” to self-antigens by
selectively eliminating specific, harmful immune responses while
leaving the rest of the immune system intact. Through a targeted
and selective approach, Tolerion’s product candidates have the
potential to deliver superior efficacy, safety and tolerability
relative to current therapies.  Tolerion’s lead product,
TOL-3021, is a novel reverse vaccine that induces tolerance to
the type 1 diabetes specific autoantigen proinsulin and thereby
reduces disease activity. Results from a phase 2a study
demonstrate that TOL-3021 is safe and preserves beta-cell
function while reducing diseas